$8.64
+0.16
(+1.89%)▲
Insights on Macrogenics, Inc.
Revenue is down for the last 4 quarters, 71.17M → 10.39M (in $), with an average decrease of 44.2% per quarter
Netprofit is down for the last 2 quarters, 57.46M → 17.55M (in $), with an average decrease of 69.5% per quarter
In the last 1 year, Seagen, Inc. has given 80.8% return, outperforming this stock by 37.8%
In the last 3 years, Novo Nordisk A/s has given 20.4% return, outperforming this stock by 83.1%
1.5%
Downside
Day's Volatility :3.19%
Upside
1.71%
50.35%
Downside
52 Weeks Volatility :50.4%
Upside
0.12%
Period | Macrogenics, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 63.64% | 0.0% | 0.0% |
6 Months | 64.57% | 2.2% | 0.0% |
1 Year | 43.05% | -4.7% | -2.1% |
3 Years | -62.68% | 18.0% | -6.5% |
Market Capitalization | 519.8M |
Book Value | $3.13 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | 0.81 |
PE Ratio | 10.35 |
PEG Ratio | 0.01 |
Wall Street Target Price | 12.11 |
Profit Margin | 41.13% |
Operating Margin TTM | -341.46% |
Return On Assets TTM | -24.96% |
Return On Equity TTM | 31.44% |
Revenue TTM | 121.1M |
Revenue Per Share TTM | 1.96 |
Quarterly Revenue Growth YOY | -75.1% |
Gross Profit TTM | -62.5M |
EBITDA | -95.9M |
Diluted Eps TTM | 0.81 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.4 |
EPS Estimate Next Year | -1.87 |
EPS Estimate Current Quarter | -0.1 |
EPS Estimate Next Quarter | -0.52 |
What analysts predicted
Upside of 40.16%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 155.5M | ↑ 79.62% |
Net Income | -19.6M | ↓ 66.47% |
Net Profit Margin | -12.62% | ↑ 54.98% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 60.1M | ↓ 61.34% |
Net Income | -171.5M | ↑ 773.6% |
Net Profit Margin | -285.18% | ↓ 272.56% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 62.0M | ↑ 3.17% |
Net Income | -151.8M | ↓ 11.46% |
Net Profit Margin | -244.76% | ↑ 40.42% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 97.8M | ↑ 57.62% |
Net Income | -117.8M | ↓ 22.42% |
Net Profit Margin | -120.48% | ↑ 124.28% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 75.6M | ↓ 22.63% |
Net Income | -190.9M | ↑ 62.04% |
Net Profit Margin | -252.31% | ↓ 131.83% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 151.9M | ↑ 100.87% |
Net Income | -120.0M | ↓ 37.11% |
Net Profit Margin | -78.99% | ↑ 173.32% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 26.0M | ↑ 143.67% |
Net Income | -40.8M | ↓ 38.41% |
Net Profit Margin | -156.88% | ↑ 463.83% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 41.7M | ↑ 60.47% |
Net Income | -24.7M | ↓ 39.53% |
Net Profit Margin | -59.11% | ↑ 97.77% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 71.2M | ↑ 70.55% |
Net Income | 12.8M | ↓ 151.89% |
Net Profit Margin | 17.99% | ↑ 77.1% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 24.2M | ↓ 65.98% |
Net Income | -38.2M | ↓ 398.77% |
Net Profit Margin | -157.96% | ↓ 175.95% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 13.1M | ↓ 45.75% |
Net Income | 57.5M | ↓ 250.25% |
Net Profit Margin | 437.49% | ↑ 595.45% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 10.4M | ↓ 20.85% |
Net Income | 17.6M | ↓ 69.45% |
Net Profit Margin | 168.84% | ↓ 268.65% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 373.9M | ↑ 20.12% |
Total Liabilities | 74.6M | ↑ 75.59% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 332.1M | ↓ 11.17% |
Total Liabilities | 89.3M | ↑ 19.57% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 312.5M | ↓ 5.91% |
Total Liabilities | 81.9M | ↓ 8.27% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 378.7M | ↑ 21.2% |
Total Liabilities | 82.9M | ↑ 1.2% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 335.2M | ↓ 11.48% |
Total Liabilities | 95.6M | ↑ 15.41% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 280.5M | ↓ 16.34% |
Total Liabilities | 138.5M | ↑ 44.79% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 218.0M | ↓ 19.67% |
Total Liabilities | 75.6M | ↓ 18.95% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 195.3M | ↓ 10.41% |
Total Liabilities | 72.4M | ↓ 4.2% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 280.5M | ↑ 43.57% |
Total Liabilities | 138.5M | ↑ 91.27% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 343.5M | ↑ 22.47% |
Total Liabilities | 234.2M | ↑ 69.17% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 305.7M | ↓ 11.02% |
Total Liabilities | 134.1M | ↓ 42.74% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 340.0M | ↑ 11.23% |
Total Liabilities | 146.0M | ↑ 8.86% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 14.4M | ↓ 132.98% |
Investing Cash Flow | 77.9M | ↓ 210.86% |
Financing Cash Flow | 35.3M | ↑ 1806.58% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -153.2M | ↓ 1163.76% |
Investing Cash Flow | 56.6M | ↓ 27.26% |
Financing Cash Flow | 105.0M | ↑ 197.02% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -134.3M | ↓ 12.38% |
Investing Cash Flow | -79.4M | ↓ 240.1% |
Financing Cash Flow | 120.0M | ↑ 14.27% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -111.9M | ↓ 16.66% |
Investing Cash Flow | -7.8M | ↓ 90.19% |
Financing Cash Flow | 174.3M | ↑ 45.32% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -143.8M | ↑ 28.54% |
Investing Cash Flow | -36.6M | ↑ 370.25% |
Financing Cash Flow | 122.8M | ↓ 29.58% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -87.0M | ↓ 39.54% |
Investing Cash Flow | 70.7M | ↓ 293.16% |
Financing Cash Flow | 1.7M | ↓ 98.65% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -49.2M | ↓ 14.79% |
Investing Cash Flow | 23.0M | ↓ 224.66% |
Financing Cash Flow | 263.0K | ↑ 610.81% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -9.4M | ↓ 80.83% |
Investing Cash Flow | 71.9M | ↑ 212.28% |
Financing Cash Flow | 1.4M | ↑ 416.73% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 29.3M | ↓ 411.19% |
Investing Cash Flow | -5.8M | ↓ 108.04% |
Financing Cash Flow | 1.4M | ↑ 0.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -12.8M | ↓ 143.77% |
Investing Cash Flow | 28.1M | ↓ 585.4% |
Financing Cash Flow | 100.1M | ↑ 7267.03% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.1M | ↓ 83.72% |
Investing Cash Flow | -113.5M | ↓ 503.9% |
Financing Cash Flow | 59.0K | ↓ 99.94% |
Sell
Neutral
Buy
Macrogenics, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Macrogenics, Inc. | 35.64% | 64.57% | 43.05% | -62.68% | -47.35% |
![]() Moderna, Inc. | 9.42% | -35.83% | -54.97% | -49.47% | 333.33% |
![]() Regeneron Pharmaceuticals, Inc. | 0.6% | 13.15% | 9.35% | 68.7% | 124.16% |
![]() Novo Nordisk A/s | -4.03% | 23.9% | 55.84% | 186.15% | 330.1% |
![]() Seagen, Inc. | 0.86% | 10.81% | 80.8% | 20.4% | 259.73% |
![]() Vertex Pharmaceuticals Incorporated | -6.55% | 8.87% | 11.3% | 55.67% | 105.25% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Macrogenics, Inc. | 10.35 | 10.35 | 0.01 | 0.4 | 0.31 | -0.25 | 0.0 | 3.13 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -12.72 | -0.22 | -0.07 | 0.0 | 35.32 |
![]() Regeneron Pharmaceuticals, Inc. | 23.18 | 23.18 | 1.75 | 42.5 | 0.17 | 0.09 | 0.01 | 234.47 |
![]() Novo Nordisk A/s | 41.18 | 41.18 | 4.02 | 2.67 | 0.89 | 0.22 | 0.01 | 20.77 |
![]() Seagen, Inc. | NA | NA | 18.53 | -4.16 | -0.28 | -0.13 | 0.03 | 13.52 |
![]() Vertex Pharmaceuticals Incorporated | 26.38 | 26.38 | 0.5 | 15.04 | 0.23 | 0.14 | 0.0 | 64.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Macrogenics, Inc. | Buy | $519.8M | -47.35% | 10.35 | 41.13% |
![]() Moderna, Inc. | Buy | $30.4B | 333.33% | 24.73 | -38.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $88.5B | 124.16% | 23.18 | 30.47% |
![]() Novo Nordisk A/s | Buy | $459.0B | 330.1% | 41.18 | 35.11% |
![]() Seagen, Inc. | Hold | $40.2B | 259.73% | NA | -32.61% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $90.5B | 105.25% | 26.38 | 35.94% |
Bellevue Group AG
BlackRock Inc
T. Rowe Price Investment Management,Inc.
Armistice Capital, LLC
Vanguard Group Inc
Millennium Management LLC
a career at macrogenics could be waiting for you! please click on "careers" ---------------------------->>> to learn more. macrogenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. macrogenics creates both differentiated molecules that are directed to novel cancer targets, as well as “bio-betters,” which are drugs designed to improve upon marketed medicines. the combination of macrogenics’ technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. these are exciting times at macrogenics and we hope that you will take the opportunity to learn more about our organization, our pipeline and to view our job opportunities!
Organization | Macrogenics, Inc. |
Employees | 357 |
CEO | Dr. Scott Koenig M.D., Ph.D. |
Industry | Health Technology |
Asymmetric Smart Alpha S&p 500 Etf
$8.64
+1.89%
Advisorshares Alpha Dna Equity Sentiment Etf
$8.64
+1.89%
Falcon's Beyond Global Inc
$8.64
+1.89%
Jaguar Global Growth Corporation I
$8.64
+1.89%
Missfresh Ltd
$8.64
+1.89%
Shuaa Partners Acquisition Corp I
$8.64
+1.89%
Rose Hill Acquisition Corp
$8.64
+1.89%
Partners Bancorp
$8.64
+1.89%
Mercantile Bank Corp
$8.64
+1.89%